DHR Stock Recent News

DHR's fourth-quarter sales increase 2.1% year over year, benefiting from the solid performance of its Life Sciences and Biotechnology segments.

The headline numbers for Danaher (DHR) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Danaher Corporation (DHR) Q4 2024 Earnings Call Transcript

Danaher (DHR) came out with quarterly earnings of $2.14 per share, missing the Zacks Consensus Estimate of $2.17 per share. This compares to earnings of $2.09 per share a year ago.

Danaher on Wednesday missed Wall Street estimates for fourth-quarter profit due to soft demand for tools and services used in drug development by its biotech and pharmaceutical clients.

WASHINGTON , Jan. 29, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the fourth quarter and full year 2024.  All results in this release reflect only continuing operations unless otherwise noted.

Investors with an interest in Diversified Operations stocks have likely encountered both Marubeni Corp. (MARUY) and Danaher (DHR). But which of these two stocks is more attractive to value investors?

DHR's Q4 results are likely to be ailed by weakness in the Biotechnology and Life Sciences segments.

Danaher (DHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

FARGO, N.D.--(BUSINESS WIRE)--Aldevron Unveils Next-Generation Alchemy™ Cell-Free DNA Technology for Research Grade Applications.